Literature DB >> 14675035

Guanylin and uroguanylin induce natriuresis in mice lacking guanylyl cyclase-C receptor.

Stephen L Carrithers1, Cobern E Ott, Michael J Hill, Brett R Johnson, Weiyan Cai, Jason J Chang, Rajesh G Shah, Congmei Sun, Elizabeth A Mann, Manasses C Fonteles, Leonard R Forte, Brian A Jackson, Ralph A Giannella, Richard N Greenberg.   

Abstract

BACKGROUND: Guanylin (GN) and uroguanylin (UGN) are intestinally derived peptide hormones that are similar in structure and activity to the diarrhea-causing Escherichia coli heat-stable enterotoxins (STa). These secretagogues have been shown to affect fluid, Na+, K+, and Cl- transport in both the intestine and kidney, presumably by intracellular cyclic guanosine monophosphate (cGMP)-dependent signal transduction. However, the in vivo consequences of GN, UGN, and STa on renal function and their mechanism of action have yet to be rigorously tested.
METHODS: We hypothesized that intravenous administration of GN, UGN, or STa would cause an increase in natriuresis in wild-type mice via cGMP and guanylyl cyclase-C (GC-C, Gucy2c), the only known receptor for these peptide-hormones, and that the peptide-induced natriuresis would be blunted in genetically altered mice devoid of GC-C receptors (GC-C(-/-) null).
RESULTS: In wild-type mice using a modified renal clearance model, GN, UGN, and STa elicited significant natriuresis, kaliuresis, and diuresis as well as increased urinary cGMP levels in a time- and dose-dependent fashion. Absolute and fractional urinary sodium excretion levels were greatest approximately 40 minutes following a bolus infusion with pharmacologic doses of these peptides. Unexpectedly, GC-C(-/-) null mice also responded to the GN peptides similarly to that observed in wild-type mice. Glomerular filtration rate (GFR), blood pressure, and plasma cGMP in the mice (wild-type or GC-C(-/-) null) did not significantly vary between the vehicle- and peptide-treatment groups. The effects of UGN may also influence long-term renal function due to down-regulation of the Na+/K+ ATPase gamma-subunit and the Cl- channel ClC-K2 by 60% and 75%, respectively, as assessed by differential display polymerase chain reaction (PCR) (DD-PCR) and Northern blot analysis of kidney mRNA from mice treated with UGN.
CONCLUSION: GN, UGN, and STa act on the mouse kidney, in part, through a cGMP-dependent, GC-C-independent mechanism, causing significant natriuresis by renal tubular processes. UGN may have further long-term effects on the kidney by altering the expression of such transport-associated proteins as Na+/K+ ATPase and ClC-K2.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14675035     DOI: 10.1111/j.1523-1755.2004.00375.x

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  33 in total

1.  Molecular staging estimates occult tumor burden in colorectal cancer.

Authors:  Alex Mejia; Stephanie Schulz; Terry Hyslop; David S Weinberg; Scott A Waldman
Journal:  Adv Clin Chem       Date:  2010       Impact factor: 5.394

Review 2.  Molecular staging individualizing cancer management.

Authors:  Alex Mejia; Stephanie Schulz; Terry Hyslop; David S Weinberg; Scott A Waldman
Journal:  J Surg Oncol       Date:  2012-04-01       Impact factor: 3.454

Review 3.  GUCY2C molecular staging personalizes colorectal cancer patient management.

Authors:  Jian P Gong; Stephanie Schulz; Terry Hyslop; Scott A Waldman
Journal:  Biomark Med       Date:  2012-06       Impact factor: 2.851

Review 4.  Immunotherapeutic strategies to target prognostic and predictive markers of cancer.

Authors:  Michael S Magee; Adam E Snook; Glen P Marszalowicz; Scott A Waldman
Journal:  Biomark Med       Date:  2013-02       Impact factor: 2.851

Review 5.  GCC signaling in colorectal cancer: Is colorectal cancer a paracrine deficiency syndrome?

Authors:  P Li; J E Lin; G P Marszlowicz; M A Valentino; C Chang; S Schulz; G M Pitari; Scott A Waldman
Journal:  Drug News Perspect       Date:  2009 Jul-Aug

6.  Receptor guanylyl cyclase C (GC-C): regulation and signal transduction.

Authors:  Nirmalya Basu; Najla Arshad; Sandhya S Visweswariah
Journal:  Mol Cell Biochem       Date:  2009-12-04       Impact factor: 3.396

7.  The natriuretic peptide uroguanylin elicits physiologic actions through 2 distinct topoisomers.

Authors:  Nicholas G Moss; Dorothy A Riguera; Robert M Solinga; Marco M Kessler; Daniel P Zimmer; William J Arendshorst; Mark G Currie; Michael F Goy
Journal:  Hypertension       Date:  2009-03-16       Impact factor: 10.190

8.  A novel role for uroguanylin in the regulation of sodium balance.

Authors:  Leonard R Forte
Journal:  J Clin Invest       Date:  2003-10       Impact factor: 14.808

Review 9.  Pendrin, a novel transcriptional target of the uroguanylin system.

Authors:  Julia Rozenfeld; Osnat Tal; Orly Kladnitsky; Lior Adler; Edna Efrati; Stephen L Carrithers; Seth L Alper; Israel Zelikovic
Journal:  Cell Physiol Biochem       Date:  2013-12-18

10.  Activation of a novel natriuretic endocrine system in humans with heart failure.

Authors:  Hafid Narayan; Noor Mohammed; Paulene A Quinn; Iain B Squire; Joan E Davies; Leong L Ng
Journal:  Clin Sci (Lond)       Date:  2010-03       Impact factor: 6.124

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.